/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...
2023 could be a year of heightened biotech dealmaking activity
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“ BELLUS Health ” or the “ Company ”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough,...
Biotech is expected to be a hotbed of mergers and acquisitions this year.
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health.
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
A wave of bargain buying benefited the gene therapy company's shares this week.
The company has received a buyout offer from GSK.
Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.